PDCD1 and neoplasm: The addition of lenvatinib to pembrolizumab, which is thought to synergize the immune response to the PD-1 blockade by decreasing the number of tumor-associated macrophages (TAMs), has shown anti-tumor effects in a number of other malignancies, including advanced endometrial cancer and hepatocellular carcinoma [17].